FDA Approves Pig Liver Clinical Trial for Liver Failure
Gene-Edited Pig Livers to be Tested as Temporary Treatment for Human Liver Failure
Table of Contents
WASHINGTON – U.S. researchers are set to begin clinical trials using gene-edited pig livers to treat patients experiencing liver failure. The approach involves temporarily filtering a patient’s blood through the pig liver, allowing their own organ to rest and potentially recover.
the Food and Drug Administration has approved the first clinical trial, according to an declaration Tuesday by Egenesis, a company specializing in genetically modified pigs, and its partner Organox.
The Associated Press reports that approximately 35,000 people in the United States are hospitalized annually due to sudden liver failure. Many of these individuals are either ineligible for a liver transplant or unable to receive one in time.
This study marks a shift in the field of xenotransplantation,the transplantation of animal organs into humans. Rather of transplanting the pig liver,researchers will use it as an external support system for study participants.
The liver possesses the unique ability to regenerate. The study aims to determine if filtering a patient’s blood for a few days can provide the necessary window for recovery.
Mike Curtis, CEO of Egenesis, based in Massachusetts, stated that “in experiments with four bodies, the ‘bridge’ effort shows the heart of pigs can support some human liver functions for two or three days.” Egenesis has genetically modified the pigs to make their organs more compatible with humans.
The trial will include up to 20 patients in intensive care units who are not candidates for liver transplantation, according to Curtis. Organox, a company based in England, will provide a device currently used to preserve donated human livers. This device will pump the participants’ blood through the pig liver.
Gene-Edited Pig Livers: A Potential Breakthrough in Liver Failure Treatment
Here’s a breakdown of this innovative approach to treating liver failure, presented in a Q&A format:
What’s the Big News?
Q: What’s happening with pig livers and human health?
A: U.S. researchers are about to start clinical trials using gene-edited pig livers to treat people with liver failure.
Q: How does this treatment work?
A: The treatment involves temporarily filtering a patient’s blood through a pig liver. This allows the patient’s own liver to rest and potentially recover.
Understanding the Problem
Q: Why is there a need for this kind of treatment?
A: According to the associated Press, around 35,000 people in the U.S. are hospitalized each year due to sudden liver failure. Often, these patients can’t get a liver transplant quickly enough or aren’t eligible.
Q: What are the current options for people with liver failure?
A: The primary option would be transplant. Unfortunately, manny individuals can be ineligible for a liver transplant or might not be able to get one in a timely manner. .
Diving into the Science
Q: What is xenotransplantation?
A: Xenotransplantation is the transplantation of animal organs into humans. This study represents a shift in this field.
Q: How is this different from a regular liver transplant?
A: Instead of transplanting the pig liver into the patient, researchers will use it as an external support system. The patient’s blood will be filtered through the pig liver.
Q: Why use a pig liver?
A: Pigs are being used because their organs are a close match to human organs and they are relatively easy to raise.
Q: What makes this project possible?
A: Egenesis, a company focused on genetically modified pigs, has modified pigs to make their organs more compatible with humans.
Q: How long will this temporary treatment last?
A: The goal is to support the patient for a few days, allowing their liver the time to regenerate.
Q: Does the human liver have the capacity to regenerate?
A: Yes, the liver does have the unique ability to regenerate.
The Clinical Trial
Q: Who is involved in these clinical trials?
A: The trials will include up to 20 patients in intensive care units who are not eligible for a liver transplant.
Q: How will the filtering process work?
A: Organox,a company based in England will provide a device that is currently used to preserve donated human livers. This device will pump the participant’s blood through the pig liver.
Q: What is the role of Egenesis in this project?
A: The CEO of egenesis, Mike curtis, stated that in experiments with four bodies, the “bridge” effort shows the heart of the pigs can support some human liver functions for two or three days. Egenesis genetically modified the pigs for this project.
Key Facts Summarized
Here’s a quick overview of the key components of this new approach:
| Feature | Details |
|---|---|
| Treatment Type | Temporary blood filtration via gene-edited pig liver (external support) |
| Target Patients | Patients with sudden liver failure, ineligible for or awaiting transplant |
| Goal | Allow patient’s liver to rest and regenerate |
| Key Companies | Egenesis (genetically modified pigs), Organox (blood filtration device) |
| Mechanism | Blood pumped through pig liver outside the patient’s body |
| trial Duration | A few days |